texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x
Request an Appointment

East Texas Clinical Trials

Texas Oncology cancer centers in east Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the east Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the east Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in a Clinical Trial

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the east Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the east Texas area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Tyler

Phase: I

Biliary Cancer

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: IV

Bladder Cancer

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Blood Cancer

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Tyler

Phase: II

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: IV

Carcinoid

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Tyler

Phase: II

Cervical Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: IV

Colon Cancer

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: IV

Endometrial Cancer

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: IV

Esophageal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Fallopian Tube Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Gall Bladder Cancer

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Gastric Cancer

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: IV

Head and Neck Cancer

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: IV

Hematologic

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Longview

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Longview

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Paris

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: IV

Hematology- Myelofibrosis

Title: An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Indication: Hematology- Myelofibrosis

Location: Texas Oncology-Tyler

Kidney Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Tyler

Phase: I

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: IV

Liver Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: IV

Lung Cancer

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SPYK04 Solid Tumors View

Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IV

Lymphoma

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphoma

Location: Texas Oncology-Longview

Phase: II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphoma

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphoma

Location: Texas Oncology-Tyler

Phase: II/III

Lymphomas

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Melanoma

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: IV

Myelodysplastic Syndrome

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: IV

Myelomas

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Ovarian Cancer

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SPYK04 Solid Tumors View

Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: IV

Pancreatic Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1/2 Azeliragon refrac to 1st Line Pancreatic View

Description: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer (CAN-201)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: IV

Peritoneal Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Prostate Cancer

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: IV

Rectal Cancer

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Renal Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Skin Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: IV

Solid Tumors

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SPYK04 Solid Tumors View

Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Testicular Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: I

Thyroid Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: IV

Urothelial Cancer

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Uterine Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: I

Vulvar Cancer

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Tyler

Phase: I

Texas Oncology-Longview

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphoma

Location: Texas Oncology-Longview

Phase: II/III

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Longview

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Longview

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: I

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: III

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Longview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview

Phase: IV

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: I/II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Longview

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Longview

Phase: I

Texas Oncology-Longview Cancer Center

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphoma

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: I/II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Texas Oncology-Palestine Cancer Center

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Texas Oncology-Paris

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Paris

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Paris

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Paris

Phase: IV

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Paris

Phase: I/II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: PH3 Tuc+Trast&mFF6 v mFF6 mCRC View

Description: SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Paris

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Paris

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Paris

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Paris

Phase: I

Texas Oncology-Tyler

Title: A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphoma

Location: Texas Oncology-Tyler

Phase: II/III

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Indication: Hematology- Myelofibrosis

Location: Texas Oncology-Tyler

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Blood Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 HR+/HER2- BC (OVELIA) View

Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4) View

Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09) View

Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6) View

Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 LY3484356 ER+ HER2- MBC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1) View

Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma View

Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)

Indication: Carcinoid

Location: Texas Oncology-Tyler

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract View

Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Tyler

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Tyler

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SPYK04 Solid Tumors View

Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. View

Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II/III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: III

Title: Ph2 Sub Mosunetuzumab B-cell malig View

Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph2 Epco r/r B-Cell Lymph out pt View

Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)

Indication: Lymphomas

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Tyler

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SPYK04 Solid Tumors View

Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1/2 Azeliragon refrac to 1st Line Pancreatic View

Description: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer (CAN-201)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Peritoneal Cancer

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph3 Abema +Abira +Predn mHSPC (Cyclone3) View

Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph2 Epidemi Colon Cancer View

Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph2 RO7198457 CRC ctDNA+ Post Resection View

Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph2 Tumor-Agnostic Precision TAPISTRY View

Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: Ph1b/2 BEMA FGFR2b ST Basket Trial View

Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I/II

Title: Ph1 SPYK04 Solid Tumors View

Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes View

Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: IV

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Testicular Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Tyler

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Tyler

Phase: II/III

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Uterine Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Vulvar Cancer

Location: Texas Oncology-Tyler

Phase: I

No Phase

Title: An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Indication: Hematology- Myelofibrosis

Location: Texas Oncology-Tyler

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Longview Cancer Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Palestine Cancer Center

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Paris

Title: Biomarker status NSCLC View

Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase I

Title: A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Indication: Solid Tumors

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Anal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Bladder Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Breast Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Cervical Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Colon Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Endometrial Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Esophageal Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Gastric Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Paris

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Kidney Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: DETECT-ASCEND 2 Plasma Based Test View

Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Longview

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Longview Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Palestine Cancer Center

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Paris

Phase: I

Title: Ph1b-XL092 Immun Onco mST View

Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)

Indication: Liver Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1 SGN-TGT Advanced Malignancies View

Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)

Indication: Lung Cancer

Location: Texas Oncology-Tyler

Phase: I

Title: Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C View

Description: 20190135: A Phase 1b Study Eva